disease np also known acid sphingomyelinase deficiency group rare genetic diseases varying severity inherited metabolic disorders sphingomyelin accumulates lysosomes cells many organs np types ab b cause mutations gene causes deficiency acid sphingomyelinase asm np type c considered separate disease involved deficiency asm disorders involve dysfunctional metabolism sphingolipids fats found cell membranes considered kind sphingolipidosis included larger family lysosomal storage symptoms related organs sphingomyelin accumulates enlargement liver spleen hepatosplenomegaly may cause reduced appetite abdominal distension pain enlargement spleen splenomegaly may also cause low levels platelets blood thrombocytopeniacitation needed accumulation sphingomyelin central nervous system including cerebellum results unsteady gait ataxia slurring speech dysarthria difficulty swallowing dysphagia basal ganglia dysfunction causes abnormal posturing limbs trunk face dystonia upper brainstem disease results impaired voluntary rapid eye movements supranuclear gaze palsy widespread disease involving cerebral cortex subcortical structures causes gradual loss intellectual abilities causing dementia seizurescitation needed bones also may affected disease causing enlarged bone marrow cavities thinned cortical bone distortion hip bone called coxa vara sleeprelated disorders also occur condition sleep inversion sleepiness day wakefulness night gelastic cataplexy sudden loss muscle tone affected patient laughs also seencitation needed mutations gene cause disease types b produce deficiency activity lysosomal enzyme acid sphingomyelinase breaks lipid mutations cause disease type c npc affects protein used transport type originally separated type c delineate group patients otherwise identical disorders shared common nova scotian ancestry patients group known share specific mutation gene npc used groups molecular defects described terms type type ii proposed separate high lowsphingomyelin forms disease early needed disease inherited autosomal recessive means copies alleles gene must defective cause disease defective means altered way impairs function often parents child autosomal recessive disorder carriers one copy altered gene affected copy produces enzyme parents carriers pregnancy chance producing affected child genetic counseling genetic testing recommended families may carriers diseasecitation needed diseases subgroup lipid storage disorders called sphingolipidoses harmful quantities fatty substances lipids accumulate spleen liver lungs bone marrow braincitation needed classic infantile typea variant missense mutation causes complete deficiency sphingomyelinase sphingomyelin component cell membrane including organellar membrane enzyme deficiency blocks degradation lipid resulting accumulation sphingomyelin within lysosomes macrophagemonocyte phagocyte lineage affected cells become enlarged sometimes Î¼m diameter secondary distention lysosomes sphingomyelin cholesterol histology shows lipidladen macrophages marrow seablue histiocytes pathology numerous small vacuoles relatively uniform size created giving cytoplasm foamy appearancecitation needed type b levels sphingomylinase measured blood sample diagnose type c skin sample help determine whether transporter affected via filipin test detects buildup unesterified cholesterol via fluorescent four types disease divided categories patients asm deficiency classified types b type patients exhibit hepatosplenomegaly infancy profound central nervous system involvement unable survive beyond two years age type b patients also show hepatosplenomegaly pathologic alterations lungs usually without involvement central nervous system develop significant lifethreatening complications including liver failure hemorrhage oxygen dependency pulmonary infections splenic rupture develop coronary arterial valvular heart disease longitudinal natural history study nearly patients died classified type c may mild hepatosplenomegaly central nervous system profoundly disease type nova scotia form believed condition disease type two poorly characterized forms disease also described types e specific treatment known type symptoms treatedcitation needed adult patients type b physicians try keep cholesterol levels normal levels statins used monitor liver function spleen enlarged platelet levels low acute episodes bleeding may require transfusions blood products symptoms interstitial lung disease may need anecdotally organ transplant attempted limited success future prospects include enzyme replacement gene therapy bone marrow transplant tried type january actelion announced drug miglustat zavesca approved european union treatment progressive neurological manifestations adult patients pediatric patients npc drug available patients united states experimental basis march fda requested additional preclinical clinical information regarding zavesca actelion making final decision approving drug united states olipudase alfa xenpozyme approved medical use japan march highly variable infantile neurovisceral niemann pick disease type asmd usually fatal years age type b severity highly variable many patients live well adulthood may reach normal lifespan diagnoses made decade life type c entirely different disorder also highly variable prognosiscitation needed incidence among ashkenazi jews estimated one type incidence disease types b populations estimated one incidence disease type c estimated one albert niemann published first description known disease type ludwig pick described pathology disease series papers classification disease types b c introduced also contained type called nova scotian type genetic studies showed type caused gene type type designation longer research ongoing better understand disease treatments however present cure loss myelin central nervous system considered main pathogenic factor research uses animal models carrying underlying mutation disease eg mutation gene seen type c disease model expression myelin gene regulatory factor mrf shown significantly mrf transcription factor critical importance development maintenance myelin perturbation oligodendrocyte maturation myelination process might therefore underlying mechanism neurological curiously fibroblast cells derived patients type disease shown resistant ebola virus mutations protein needed viral escape vesicular studies uncovered small molecules inhibit receptor may potential therapeutic european medicines agency granted orphan drug designation arimoclomol treatment type followed us food drug dosing placebocontrolled phase iiiii clinical trial investigate treatment type c patients type using arimoclomol began researchers university arizona first proposed use treatment type researchers noted hpbcds varying levels substitution effects delaying neurological symptoms decreasing liver cholesterol storage mouse model later researchers university texas southwestern medical center found type c mice injected hpbcd seven days old showed marked improvement liver function much less neurodegeneration ultimately lived longer lives mice receive treatment results suggest hpbcd acutely reverses storage defect seen april us national institutes health collaboration therapeutics rare neglected diseases announced developing clinical trial using hpbcd type patients clinical trial conducted vtesse llc began january completed march april european medicines agency granted international disease alliance united kingdom orphan designation hpbcd treatment disease type gene therapy used clinically treat genetic diseases including haemophilia spinal muscular atrophy used preclinically mouse model type c using adenoassociated virusderived viral vector shown extend lifespan following injection lateral ventricles neonatal separate proofofconcept study similar vector modified capsid injected intravenously type c mice around four weeks age resulted extended lifespan improved weight gene therapy also used preclinically mouse model type injection cisterna magna seven weeks age prevented motor memory impairment neuronal cell